Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Biomarkers
Cardiovascular Diseases
Cholesterol, LDL
Comorbidity
Down-Regulation
Drug Therapy, Combination
Dyslipidemias
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Proprotein Convertase 9
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Serine Proteinase Inhibitors
Time Factors
Treatment Outcome

authors with profiles

Michael H. Davidson